Clinical Trial Update: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor [Phase 3]

View source ↗

Summary

Phase 3 trial comparing [18F] LBT-999 PET imaging to DaTSCAN ([123I]-FP/CIT SPECT) for distinguishing Parkinson disease from essential tremor has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Tremor
• Parkinson Disease

Drugs mentioned

• DaTSCAN ([123I]-FP/CIT SPECT) (Iodine-123 FP-CIT SPECT)
• [18F] LBT-999 PET (18F-LBT-999 PET tracer)

Snippet

Sponsor: GE Healthcare | Conditions: Parkinson Disease, Essential Tremor | Phase 3 | Status: COMPLETED